A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Schizophrenic Patients With Agitation

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Schizophrenic Patients With Agitation

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2008

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 01 May 2008 Results will be presented at the 161st American Psychiatric Association annual meeting in May.
    • 23 Jan 2007 Status change from in progress to completed.
    • 23 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top